Drug survival higher for ixekizumab vs secukinumab in moderate-to-severe plaque psoriasis
More patients with moderate-to-severe plaque psoriasis discontinued treatment with secukinumab despite receiving significantly fewer biologics prior to initiating this drug as compared with those treated with ixekizumab, a recent study has shown.
Secukinumab and ixekizumab were administered to 368 and 62 patients, respectively. The corresponding proportion of bionaive patients was 40.7 percent and 12.9 percent. In addition, patients treated with ixekizumab had been given significantly more biologics in the past.
Of the bionaive patients, 23.5 percent in the secukinumab arm and none in the ixekizumab arm discontinued therapy over 12 months. Drug survival for bionaive and non-naïve patients was higher for ixekizumab than for secukinumab.
During the maximum follow-up of 3 years, drug survival among secukinumab users was lowest for those who have previously received two or more biologics, followed by those who received secukinumab as their second-ever biologic.
In this study, the authors used the DERMBIO registry to examine the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with moderate-to-severe psoriasis in Denmark. Danish patients receiving treatment with either drug based on standard in-label dosing were included in the analysis. Survival curves were presented using Kaplan-Meier plots.
The study was limited by its relatively small sample size and the short follow-up duration.
“Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce,” the authors said.